Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Canagliflozin/Metformin XR FDC in Healthy Subjects
NCT02039245Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma concentration of canagliflozin at Day 7 and Plasma concentration of metformin at Day 7. Started Jan 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02039245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039245.